STAA
STAAR Surgical Company NASDAQ Listed Feb 24, 1992$27.28
Mkt Cap $1.4B
52w Low $15.59
76.8% of range
52w High $30.81
50d MA $21.70
200d MA $23.59
P/E (TTM)
-16.8x
EV/EBITDA
-28.4x
P/B
3.9x
Debt/Equity
0.1x
ROE
-23.4%
P/FCF
-29.2x
RSI (14)
—
ATR (14)
—
Beta
1.04
50d MA
$21.70
200d MA
$23.59
Avg Volume
1.3M
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
25651 Atlantic Ocean Drive · Lake Forest, CA 92630 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | AMC | 0.18 | -0.20 | -211.1% | 18.92 | -6.6% | +1.6% | -3.4% | -0.6% | -0.8% | -5.9% | — |
| Nov 5, 2025 | AMC | 0.18 | 0.46 | +155.6% | 25.25 | +0.4% | +5.5% | -0.3% | +3.2% | -0.0% | -5.7% | — |
| Aug 6, 2025 | AMC | -0.56 | -0.07 | +87.5% | 26.90 | +0.0% | +0.2% | +1.2% | +0.1% | +0.3% | +3.0% | — |
| May 7, 2025 | AMC | -0.59 | -0.52 | +11.9% | 19.44 | -5.9% | +0.5% | -0.6% | +4.4% | -6.3% | -8.3% | — |
| Feb 11, 2025 | AMC | 0.02 | -0.50 | -2600.0% | 21.88 | -33.7% | -24.7% | -3.2% | -3.8% | +8.3% | +6.9% | — |
| Oct 30, 2024 | AMC | 0.19 | 0.37 | +94.7% | 29.49 | +6.2% | -1.7% | -1.5% | +2.0% | +3.0% | +2.8% | — |
| Aug 7, 2024 | AMC | 0.25 | 0.33 | +32.0% | 36.35 | +12.0% | +11.0% | -4.9% | +0.4% | -4.7% | -4.4% | — |
| May 7, 2024 | AMC | 0.05 | 0.06 | +20.0% | 46.65 | -3.5% | -12.1% | +4.5% | -1.2% | +2.9% | +0.2% | — |
| Feb 26, 2024 | AMC | 0.19 | 0.24 | +26.3% | 31.75 | +3.9% | +2.9% | -3.4% | -1.0% | +6.6% | +3.6% | — |
| Nov 1, 2023 | AMC | 0.20 | 0.30 | +50.0% | 43.32 | -10.4% | -16.9% | +5.0% | -8.8% | +1.4% | -3.5% | — |
| Aug 2, 2023 | AMC | 0.32 | 0.40 | +25.0% | 52.30 | -14.0% | -9.6% | +2.3% | -3.5% | +0.3% | -2.9% | — |
| May 3, 2023 | AMC | 0.11 | 0.18 | +63.6% | 70.09 | -1.6% | -7.8% | +4.2% | +0.4% | -1.9% | +1.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 9 | Wedbush | Maintains | Neutral → Neutral | — | $20.88 | $24.85 | +19.0% | +20.7% | +4.9% | +1.5% | -9.0% | +1.2% |
| Apr 9 | Canaccord Genuity | Upgrade | Hold → Buy | — | $20.88 | $24.85 | +19.0% | +20.7% | +4.9% | +1.5% | -9.0% | +1.2% |
| Mar 5 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $19.22 | $18.93 | -1.5% | -3.4% | -0.6% | -0.8% | -5.9% | +2.5% |
| Mar 4 | Stifel | Maintains | Hold → Hold | — | $18.92 | $17.67 | -6.6% | +1.6% | -3.4% | -0.6% | -0.8% | -5.9% |
| Feb 9 | Stifel | Maintains | Hold → Hold | — | $17.58 | $17.47 | -0.6% | -1.0% | -0.6% | -0.3% | -4.4% | -2.4% |
| Jan 28 | Jefferies | Maintains | Buy → Buy | — | $19.04 | $18.94 | -0.5% | +0.6% | -1.1% | +0.1% | -4.8% | +0.6% |
| Jan 16 | Canaccord Genuity | Maintains | Hold → Hold | — | $20.97 | $20.53 | -2.1% | +0.0% | +0.0% | -1.7% | -3.5% | -3.8% |
| Dec 10 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $25.39 | $23.63 | -6.9% | -5.5% | +2.9% | -2.2% | -2.4% | +5.3% |
| Dec 10 | Canaccord Genuity | Maintains | Hold → Hold | — | $25.39 | $23.63 | -6.9% | -5.5% | +2.9% | -2.2% | -2.4% | +5.3% |
| Aug 7 | Stifel | Downgrade | Buy → Hold | — | $26.90 | $26.90 | +0.0% | +0.2% | +1.2% | +0.1% | +0.3% | +3.0% |
| Aug 6 | Canaccord Genuity | Maintains | Hold → Hold | — | $27.02 | $27.05 | +0.1% | -0.4% | +0.2% | +1.2% | +0.1% | +0.3% |
| Aug 5 | Sidoti & Co. | Downgrade | Buy → Neutral | — | $18.49 | $26.77 | +44.8% | +46.1% | -0.4% | +0.2% | +1.2% | +0.1% |
| Jul 16 | Mizuho | Maintains | Neutral → Neutral | — | $16.86 | $17.22 | +2.1% | +1.4% | +1.1% | +0.5% | +2.3% | +2.9% |
| May 27 | Canaccord Genuity | Maintains | Hold → Hold | — | $18.68 | $18.96 | +1.5% | +1.3% | -4.4% | +1.4% | -2.8% | -6.3% |
| May 21 | Needham | Maintains | Hold → Hold | — | $19.24 | $19.07 | -0.9% | -4.1% | +1.7% | -0.5% | +1.3% | -4.4% |
| May 8 | Canaccord Genuity | Maintains | Hold → Hold | — | $19.44 | $18.30 | -5.9% | +0.5% | -0.6% | +4.4% | -6.3% | -8.3% |
| Mar 18 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $17.61 | $16.45 | -6.6% | +3.8% | -0.2% | -1.8% | -1.1% | +0.3% |
| Feb 27 | Needham | Maintains | Hold → Hold | — | $17.09 | $16.62 | -2.8% | +3.5% | -1.1% | -5.9% | +7.8% | +2.4% |
| Feb 13 | Canaccord Genuity | Maintains | Hold → Hold | — | $16.48 | $16.32 | -1.0% | -3.2% | -3.8% | +8.3% | +6.9% | -5.2% |
| Feb 12 | William Blair | Downgrade | Outperform → Market Perform | — | $21.88 | $14.50 | -33.7% | -24.7% | -3.2% | -3.8% | +8.3% | +6.9% |
| Feb 12 | Stifel | Maintains | Buy → Buy | — | $21.88 | $14.50 | -33.7% | -24.7% | -3.2% | -3.8% | +8.3% | +6.9% |
| Feb 12 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $21.88 | $14.50 | -33.7% | -24.7% | -3.2% | -3.8% | +8.3% | +6.9% |
| Feb 12 | Piper Sandler | Maintains | Neutral → Neutral | — | $21.88 | $14.50 | -33.7% | -24.7% | -3.2% | -3.8% | +8.3% | +6.9% |
| Feb 12 | Needham | Maintains | Hold → Hold | — | $21.88 | $14.50 | -33.7% | -24.7% | -3.2% | -3.8% | +8.3% | +6.9% |
| Jan 7 | Needham | Maintains | Hold → Hold | — | $23.33 | $23.30 | -0.1% | +2.4% | -3.2% | -0.5% | -2.3% | -3.7% |
| Dec 9 | Canaccord Genuity | Maintains | Hold → Hold | — | $25.31 | $25.87 | +2.2% | +3.8% | +0.6% | -4.5% | +0.6% | -2.1% |
| Nov 1 | Canaccord Genuity | Maintains | Hold → Hold | — | $28.99 | $28.75 | -0.8% | -1.5% | +2.0% | +3.0% | +2.8% | +1.9% |
| Aug 26 | Stifel | Maintains | Buy → Buy | — | $33.27 | $33.05 | -0.7% | -1.7% | -1.0% | -1.4% | +0.7% | +3.0% |
| Aug 8 | Canaccord Genuity | Maintains | Hold → Hold | — | $36.35 | $40.72 | +12.0% | +11.0% | -4.9% | +0.4% | -4.7% | -4.4% |
| Jul 15 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $47.11 | $44.48 | -5.6% | -4.0% | +1.3% | -3.5% | -2.5% | -1.5% |
| Jul 15 | BTIG | Maintains | Buy → Buy | — | $47.11 | $44.48 | -5.6% | -4.0% | +1.3% | -3.5% | -2.5% | -1.5% |
| Jun 11 | BTIG | Upgrade | Neutral → Buy | — | $38.07 | $39.83 | +4.6% | +1.7% | +6.0% | +2.1% | -1.6% | -2.8% |
| May 8 | Piper Sandler | Maintains | Neutral → Neutral | — | $46.65 | $45.00 | -3.5% | -12.1% | +4.5% | -1.2% | +2.9% | +0.2% |
| May 8 | Mizuho | Maintains | Buy → Buy | — | $46.65 | $45.00 | -3.5% | -12.1% | +4.5% | -1.2% | +2.9% | +0.2% |
| May 8 | Canaccord Genuity | Maintains | Hold → Hold | — | $46.65 | $45.00 | -3.5% | -12.1% | +4.5% | -1.2% | +2.9% | +0.2% |
| Apr 11 | Mizuho | Maintains | Buy → Buy | — | $51.08 | $51.81 | +1.4% | +1.0% | -3.5% | -7.2% | +0.9% | -0.6% |
| Apr 8 | Canaccord Genuity | Maintains | Hold → Hold | — | $48.68 | $48.92 | +0.5% | +1.7% | +5.6% | -2.2% | +1.0% | -3.5% |
| Apr 1 | Stifel | Maintains | Buy → Buy | — | $38.28 | $38.95 | +1.8% | +2.0% | +1.3% | -1.2% | +16.5% | +7.0% |
| Mar 11 | Stifel | Upgrade | Hold → Buy | — | $35.86 | $38.58 | +7.6% | +8.1% | -2.9% | +1.4% | -0.3% | -0.8% |
| Feb 28 | Mizuho | Maintains | Buy → Buy | — | $32.68 | $31.97 | -2.2% | -3.4% | -1.0% | +6.6% | +3.6% | -3.5% |
| Feb 27 | Piper Sandler | Maintains | Neutral → Neutral | — | $31.75 | $33.00 | +3.9% | +2.9% | -3.4% | -1.0% | +6.6% | +3.6% |
| Dec 5 | Needham | Downgrade | Buy → Hold | — | $32.29 | $31.17 | -3.5% | -4.6% | -0.6% | +2.4% | +6.6% | -3.8% |
| Nov 2 | Piper Sandler | Maintains | Neutral → Neutral | — | $43.32 | $38.80 | -10.4% | -16.9% | +5.0% | -8.8% | +1.4% | -3.5% |
| Nov 2 | Needham | Maintains | Buy → Buy | — | $43.32 | $38.80 | -10.4% | -16.9% | +5.0% | -8.8% | +1.4% | -3.5% |
| Sep 22 | Stifel | Maintains | Hold → Hold | — | $39.39 | $40.04 | +1.7% | +0.1% | +4.4% | -1.7% | -1.5% | +0.3% |
| Sep 15 | Piper Sandler | Maintains | Neutral → Neutral | — | $42.87 | $41.95 | -2.1% | +1.1% | -3.1% | -1.6% | -1.6% | -3.1% |
| Sep 15 | Benchmark | Downgrade | Buy → Hold | — | $42.87 | $41.95 | -2.1% | +1.1% | -3.1% | -1.6% | -1.6% | -3.1% |
| Sep 15 | Mizuho | Maintains | Buy → Buy | — | $42.87 | $41.95 | -2.1% | +1.1% | -3.1% | -1.6% | -1.6% | -3.1% |
| Sep 15 | Needham | Maintains | Buy → Buy | — | $42.87 | $41.95 | -2.1% | +1.1% | -3.1% | -1.6% | -1.6% | -3.1% |
| Sep 13 | Stifel | Maintains | Hold → Hold | — | $44.90 | $44.62 | -0.6% | -2.2% | -2.4% | +1.1% | -3.1% | -1.6% |
No insider trades available.
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
STAAR's Q1 2026 net sales expected to exceed $90 million, more than doubling year-over-year, signaling strong demand for its eye surgery products and justifying a significant upward stock revaluation.
Apr 8
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Without seeing the actual press release content in Exhibit 99.1, I cannot provide specific stock impact analysis, as the "transition described above" is not included in your summary.
Please share the full filing details or the press release text for accurate assessment.
Mar 24
8-K · 7.01
! Medium
Staar Surgical Co -- 8-K 7.01: Regulation FD Disclosure
Staar Surgical will hold a conference call on March 3, 2026 to discuss Q4 and full-year 2025 financial results with interim co-CEOs presenting operational and financial performance.
Mar 3
8-K · 5.02
!!! Very High
Staar Surgical Co -- 8-K 5.02: Executive Change
STAAR Surgical's Chief Legal Officer Nathaniel Sisitsky terminated employment effective February 4, 2026, requiring investors to monitor leadership transition implications and potential interim management arrangements.
Feb 5
8-K · 5.02
!!! Very High
Staar Surgical Co -- 8-K 5.02: Executive Change
Staar Surgical appoints Warren Foust as CEO effective February 1, 2026, promoting the CFO to Vice President, signaling leadership transition that may affect operational strategy and investor confidence.
Feb 2
Data updated apr 27, 2026 3:04am
· Source: massive.com